

Resource Summary Report

Generated by PRECISE-TBI on Jul 29, 2026

Recombinant Anti-CD103 antibody [EPR22590-27]

RRID:AB_2936238

Type: Antibody

Proper Citation

Abcam Cat# ab224202, RRID:AB_2936238

Antibody Information

URL: http://antibodyregistry.org/AB_2936238

Proper Citation: Abcam Cat# ab224202, RRID:AB_2936238

Target Antigen: CD103

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: WB, IHC-P, IHC-Fr

Antibody Name: Recombinant Anti-CD103 antibody [EPR22590-27]

Description: This recombinant monoclonal targets CD103

Target Organism: Human, Rat, Mouse

Clone ID: EPR22590-27

Antibody ID: AB_2936238

Vendor: Abcam

Catalog Number: ab224202

Record Creation Time: 20250819T231321+0000

Record Last Update: 20250820T044004+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-CD103 antibody [EPR22590-27].

No alerts have been found for Recombinant Anti-CD103 antibody [EPR22590-27].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Menze A, et al. (2025) A preclinical model for the identification of therapeutically active transgenes in local cancer immunotherapy. *Oncoimmunology*, 14(1), 2543620.

Huang L, et al. (2025) Interferon-driven CAF reprogramming augments immunogenic response to neoadjuvant radiotherapy in colorectal cancer. *Cell reports. Medicine*, 6(8), 102251.

Chen D, et al. (2025) Ce6 derivative photodynamic therapy triggers PANoptosis and enhances antitumor immunity with LAG3 blockade in cutaneous squamous cell carcinoma. *Cell reports. Medicine*, 6(7), 102239.

Son HG, et al. (2024) Commensal papillomavirus immunity preserves the homeostasis of highly mutated normal skin. *Cancer cell*.

Huang CX, et al. (2024) Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma. *Cancer cell*, 42(12), 2082.

Liu X, et al. (2023) Interventional hydrogel microsphere vaccine as an immune amplifier for activated antitumour immunity after ablation therapy. *Nature communications*, 14(1), 4106.